Blog
IQVIA at DIA 2022: DAY 1 Recap
Jun 20, 2022

It’s that time of year again – the 2022 Drug Information Association (DIA) Global Annual Meeting kicked-off today in Chicago! As DIA returns to in-person programming, the IQVIA and IQVIA Laboratories teams are excited to join fellow research and development (R&D) stakeholders, regulators, patients and more as we come together to tackle global and local challenges impacting patients around the world.

Recognizing patients are at the core of all we do as an industry, DIA is an opportunity to break down information silos, learn from one another and collaborate across organizations, regions and languages to help accelerate drug development. And, this year, DIA is officially designated as a “Patients Included” conference, where the organization is emphasizing its commitment to integrating patients as experts in living with their condition, providing tangible perspectives in sessions throughout the week.

Whether meeting new colleagues and patients and reconnecting face-to-face with those we know, DIA will set the stage for ongoing, meaningful dialogue and ideas that push forward scientific and medical innovation for those in need.

Through several educational sessions and panel presentations, IQVIA leaders are actively providing thoughtful insights on various topics that are top of mind for attendees and the industry:

  • During a pre-conference virtual presentation, “Real World Evidence (RWE): The Evolving Landscape of Regulators, Data and Integrated Use,” that took place on June 14, IQVIA’s Global Head of Epidemiology for Real World Solutions Jaclyn Bosco and Matthew Reynolds, vice president of Real World Evidence, provided an overview of how RWE is currently used for evidence generation in major markets and how it can be useful for health technology assessments for payers. Both also provided an update on the current status of the U.S. Food and Drug Administration’s (FDA) guidance on when real-world studies will be sufficient to meet regulatory evidence requirements. Matthew and Jaclyn also included an update on the European Medicines Agency’s activities regarding the use of real-world data.
  • Earlier today, President of Design and Delivery Innovation at IQVIA and Chair-Elect of the DIA Board of Directors Cynthia Verst moderated the opening plenary, “The Future of Healthcare,” where experts in pharmaceuticals, regulatory, academia, digital health, patient advocacy and more discussed important topics for the future of healthcare, including the need for diversity and inclusion in drug development, the need for stronger collaboration among stakeholders and further focus on patient preferences and satisfaction and more. She later led an Innovation Theater presentation titled, “Redefining Patient Centricity in a Post-Pandemic Era.” As the global COVID-19 pandemic forced our industry to think beyond the status quo, Cynthia discussed the innovative ways IQVIA successfully engaged patients, leveraged transformative technologies and accelerated trial processes by keeping focus on one thing: patient centricity. Looking ahead, the session explored how to take the best of these innovations and turn them into patient-centric best practices for future clinical trials.
  • Paula Butler, senior director of Operational Transformation and Performance at IQVIA, joined a panel of clinical trial operational and management experts for the “Risk-Based Monitoring in Clinical Trials: An Evolution of Practices during the COVID-19 Pandemic” forum. Paula and fellow panelists reported insights from a two-year analysis conducted for more than 6,000 trials to gauge how risk-based approaches are being used and to identify what components (e.g., centralized monitoring) were more or less adopted during the pandemic.

It’s good to be back on-site this year! As such, please visit our IQVIA booth (#1300) and IQVIA Laboratories booth (#1209) to chat with us about your work and related needs and to learn more about our new and existing capabilities and solutions. Stop by and try out some of our key solutions for yourself through several demo stations we’ve included at the IQVIA booth, focusing on decentralized trials, patient recruitment, drug discovery and development, electronic clinical outcome assessment (eCOA) digital trial management and data analytics and digital site suite.

We’ve had a great start to DIA 2022, and there is much more to come over the next few days. Stay tuned for more daily recaps throughout DIA on key takeaways from meaningful conversations with fellow stakeholders aiming to help improve patients’ lives together.

For questions, contact us here.

Contact Us